Description
Medicube Zero Pore Pad Mild is a gentle, hypoallergenic daily toner pad tailored for sensitive skin that experiences pore congestion, excess sebum, or texture issues. Unlike the original Zero Pore Pad 2.0 (which relies on AHA and BHA), this mild version uses PHA (Polyhydroxy Acid)—a larger molecule acid that exfoliates dead surface skin without causing stinging or irritation. Combined with soothing botanicals, Panthenol, Madecassoside, and Hyaluronic Acid, it balances oil-water levels, minimizes the appearance of pores, and strengthens the skin moisture barrier.
How to Use
-
Cleanse: Wash your face thoroughly and pat dry.
-
Embossed Side First: Take one pad and gently wipe the embossed side across the face, focusing on areas with excess oil, rough texture, or enlarged pores (T-zone, nose, chin). Avoid the sensitive eye and mouth areas.
-
Silky Side Next: Flip the pad over to the smooth (silky) side and swipe across the entire face once more to pick up residual impurities and smooth skin texture.
-
Absorb & Follow Up: Lightly pat any remaining essence into the skin until absorbed. Follow with your regular ampoule/serum and moisturizer.
-
Frequency: Gentle enough for daily use (morning and/or night). If using in the morning, finish with sunscreen.
Ingredient Names
-
Water (Aqua)
-
Dipropylene Glycol
-
Glycereth-26
-
Glycerin
-
Gluconolactone (PHA)
-
1,2-Hexanediol
-
Hydroxyacetophenone
-
Tromethamine
-
Panthenol
-
Allantoin
-
Polyglyceryl-10 Laurate
-
Ethylhexylglycerin
-
Disodium EDTA
-
Xanthan Gum
-
Butylene Glycol
-
Sodium Hyaluronate
-
Madecassoside
-
Centella Asiatica Extract
-
Melaleuca Alternifolia (Tea Tree) Leaf Extract
-
Oenothera Biennis (Evening Primrose) Flower Extract
-
Pinus Palustris Leaf Extract
-
Pueraria Lobata Root Extract
-
Ulmus Davidiana Root Extract
-
Hydroxypropyltrimonium Hyaluronate
-
Hydrolyzed Hyaluronic Acid
-
Sodium Acetylated Hyaluronate
-
Hyaluronic Acid
-
Hydrolyzed Sodium Hyaluronate
-
Sodium Hyaluronate Crosspolymer
-
Potassium Hyaluronate





Reviews
There are no reviews yet.